Abeer Eddib, MD
Urogynecology and Reconstructive Pelvic Surgery · Cheektowaga, NYNPI 1215954102
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,625 of the $19,080 with a category attached, or 60.9%. Stryker accounts for 72.3% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $13,796, 9.8 times the $1,404 reported in 2019. Among urogynecology and reconstructive pelvic surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $276.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$14K
- Medtronic$1K
- Johnson & Johnson$1K
- Intuitive Surgical$782
- Applied Medical Resources Corporation$748
- Valencia Technologies Corporation$543
- plus $863 from 9 others
What the payments were for
- Consulting fees$11,62561%
- Travel & lodging$5,47429%
- Food & beverage$1,8119%
- Gifts$1701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 11 | $13,789 |
| Medtronic(2 entities) | 18 | $1,305 |
| Johnson & Johnson | 1 | $1,050 |
| Intuitive Surgical | 5 | $782 |
| Applied Medical Resources Corporation | 2 | $748 |
| Valencia Technologies Corporation | 1 | $543 |
| Caldera Medical, Inc | 5 | $342 |
| Astellas Pharma US Inc | 13 | $228 |
| Pfizer | 5 | $78 |
| Gynesonics, Inc. | 1 | $62 |
| Boston Scientific | 2 | $54 |
| Axonics, Inc. | 2 | $51 |
| Olympus America Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- 1788$13,689
- FLEXIBLE GUIDE PIN (STRYKER ACL VERSITOMIC)$10,575
- STRATAFIX$1,050
- INTERSTIM$946
- Da Vinci Surgical System$730
- GelPOINT V-Path$702
- eCoin Device Kit$543
- Desara$117
How this compares
$19,080 in reported general payments places this provider in the 90th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
See all urogynecology and reconstructive pelvic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 151 | $153,574 |
| MyrbetriqMirabegron | 63 | $41,306 |
| Estradiol | 452 | $39,256 |
| YuvafemEstradiol | 16 | $3,225 |
| Trospium Chloride ErTrospium Chloride | 12 | $2,969 |
| Trospium Chloride | 56 | $2,968 |
| Trimethoprim | 34 | $1,637 |
| Solifenacin Succinate | 14 | $799 |
| Tamsulosin Hcl | 59 | $596 |
| NitrofurantoinNitrofurantoin Macrocrystal | 18 | $471 |
| Clobetasol Propionate | 14 | $444 |
| Nystatin | 34 | $355 |
| Cephalexin | 15 | $334 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $127 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 84 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $16 | $153,574151 claims |
| Astellas Pharma US IncMyrbetriq | $228 | $41,30663 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
Other urogynecology and reconstructive pelvic surgery in Cheektowaga
- David AbramowitzCheektowaga$5K
- Teresa DanforthCheektowaga$4K
- Sarah WardCheektowaga$3K
- Jason KimStony Brook$346K
- Dara ShalomGreat Neck$94K
- Harvey WinklerGreat Neck$81K
- Robert MoldwinNew Hyde Park$35K
- Nitya AbrahamBronx$24K
- Cornelius VerhoestPoughkeepsie$21K
- Wai LeeNew Hyde Park$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.